A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 116,000 shares of ALNY stock, worth $27.4 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
116,000
Previous 254,000 54.33%
Holding current value
$27.4 Million
Previous $61.7 Million 48.3%
% of portfolio
0.06%
Previous 0.12%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$233.81 - $287.01 $32.3 Million - $39.6 Million
-138,000 Reduced 54.33%
116,000 $31.9 Million
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $36.4 Million - $62.7 Million
254,000 New
254,000 $61.7 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $43.6 Million - $73.1 Million
315,000 Added 185.29%
485,000 $97.1 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $11.8 Million - $16.5 Million
97,700 Added 135.13%
170,000 $24.8 Million
Q1 2022

May 16, 2022

SELL
$127.18 - $173.91 $7.63 Million - $10.4 Million
-60,000 Reduced 45.35%
72,300 $11.8 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $21.1 Million - $27.7 Million
132,300 New
132,300 $22.4 Million
Q2 2018

Aug 14, 2018

SELL
$88.31 - $107.8 $21.2 Million - $25.9 Million
-240,000 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$115.92 - $148.54 $5.8 Million - $7.43 Million
-50,000 Reduced 17.24%
240,000 $28.6 Million
Q4 2017

Feb 14, 2018

BUY
$114.49 - $139.98 $33.2 Million - $40.6 Million
290,000
290,000 $36.8 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.